Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study.

IF 12.8 1区医学 Q1 DERMATOLOGY

Journal of the American Academy of Dermatology Pub Date : 2025-01-01 Epub Date: 2024-09-30 DOI:10.1016/j.jaad.2024.09.037

Yoshihito Minami, Junichiro Hiruma, Kazuharu Harada, Kazuki Fujimori, Risa Suzuki, Miho Mori, Masahiro Okura, Namiko Abe, Kazutoshi Harada, Yukari Okubo

{"title":"Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study.","authors":"Yoshihito Minami, Junichiro Hiruma, Kazuharu Harada, Kazuki Fujimori, Risa Suzuki, Miho Mori, Masahiro Okura, Namiko Abe, Kazutoshi Harada, Yukari Okubo","doi":"10.1016/j.jaad.2024.09.037","DOIUrl":null,"url":null,"abstract":"Background: The risk of fungal infection in patients with psoriasis receiving biologics is not fully understood in clinical practice.Objective: To assess the incidence and the risk of fungal infection onset in patients with psoriasis receiving biologics.Methods: A retrospective cohort study of 592 psoriasis cases treated with biologics at a single center.Results: Seventy-three (12.3%) of the 592 cases involved a fungal infection. Fungal infection occurrence was more frequently associated with the use of interleukin (IL) 17 inhibitors than of other biologics. The risk factors of fungal infection were the type of biologic agent (P = .004), age at the start of biologic therapy (odds ratio, 1.04; 95% CI, 1.02-1.06), and diabetes mellitus (odds ratio, 2.40; 95% CI, 1.20-4.79).Limitations: The present, retrospective study did not include patients who did not receive biologic therapy. Moreover, the type of biologic agent used was changed in many cases.Conclusions: Patients with psoriasis treated with IL-17 inhibitors were more likely to cause fungal infections, especially candidiasis, than other biologics. Moreover, the age at the start of biologic therapy and diabetes mellitus onset were also independent risk factors of fungal infection.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"108-115"},"PeriodicalIF":12.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2024.09.037","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The risk of fungal infection in patients with psoriasis receiving biologics is not fully understood in clinical practice.

Objective: To assess the incidence and the risk of fungal infection onset in patients with psoriasis receiving biologics.

Methods: A retrospective cohort study of 592 psoriasis cases treated with biologics at a single center.

Results: Seventy-three (12.3%) of the 592 cases involved a fungal infection. Fungal infection occurrence was more frequently associated with the use of interleukin (IL) 17 inhibitors than of other biologics. The risk factors of fungal infection were the type of biologic agent (P = .004), age at the start of biologic therapy (odds ratio, 1.04; 95% CI, 1.02-1.06), and diabetes mellitus (odds ratio, 2.40; 95% CI, 1.20-4.79).

Limitations: The present, retrospective study did not include patients who did not receive biologic therapy. Moreover, the type of biologic agent used was changed in many cases.

Conclusions: Patients with psoriasis treated with IL-17 inhibitors were more likely to cause fungal infections, especially candidiasis, than other biologics. Moreover, the age at the start of biologic therapy and diabetes mellitus onset were also independent risk factors of fungal infection.

查看原文本刊更多论文

接受生物制剂治疗的银屑病患者真菌感染的风险：一项回顾性单中心队列研究。

背景：接受生物制剂治疗的银屑病患者中真菌感染的风险尚不完全清楚：在临床实践中，接受生物制剂治疗的银屑病患者发生真菌感染的风险尚不完全清楚：评估接受生物制剂治疗的银屑病患者真菌感染的发生率和发病风险：方法：对一个中心接受生物制剂治疗的592例银屑病患者进行回顾性队列研究：592例病例中有73例（12.3%）涉及真菌感染。与其他生物制剂相比，真菌感染的发生与使用白细胞介素（IL）-17抑制剂的关系更为密切。真菌感染的风险因素包括生物制剂的类型（P = .004）、开始接受生物制剂治疗时的年龄（几率比 [OR]：1.04；95% 置信区间 [CI]：1.02-1.06）和糖尿病（OR：2.40；95% CI：1.20-4.79）：本回顾性研究不包括未接受生物治疗的患者。此外，许多病例中使用的生物制剂类型发生了改变：结论：与其他生物制剂相比，接受 IL-17 抑制剂治疗的银屑病患者更容易引发真菌感染，尤其是念珠菌病。此外，开始接受生物制剂治疗时的年龄和糖尿病的发病年龄也是真菌感染的独立风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.